What is Arvinas?
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its proprietary PROTAC platform. By focusing on the selective degradation of disease-causing proteins, the company is addressing critical unmet needs in oncology, neurology, and other serious medical conditions. Its research-driven methodology positions it at the forefront of precision medicine, enabling the development of innovative therapeutics that target previously undruggable proteins. As a leader in this specialized field, Arvinas continues to leverage its scientific expertise to expand the boundaries of modern pharmacology and patient care.
How much funding has Arvinas raised?
Arvinas has raised a total of $234.8M across 5 funding rounds:
Corporate Investment
$3.3M
Series A
$15M
Series B
$41.6M
Series C
$55M
Stock Offering
$120M
Corporate Investment (2013): $3.3M with participation from Connecticut Department of Economic and Community Development and Connecticut Innovations
Series A (2013): $15M led by Connecticut Innovations, Elm Street Ventures, 5AM Ventures, and Canaan Partners
Series B (2015): $41.6M supported by RA Capital Management, OrbiMed, Canaan Partners, New Leaf Venture Partners, and 5AM Ventures
Series C (2018): $55M featuring Sirona Capital, RA Capital Management, OrbiMed, New Leaf Venture Partners, 5AM Ventures, Nextech Invest, Canaan Partners, Deerfield, and Hillhouse Capital
Stock Issuance/Offering (2018): $120M backed by Undisclosed
Key Investors in Arvinas
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains, managing capital across biopharmaceuticals, medical devices, and digital health.
What's next for Arvinas?
Looking ahead, Arvinas is well-positioned to leverage its substantial capital reserves to accelerate clinical development and expand its therapeutic reach. The company's strategic focus remains on validating its PROTAC technology across diverse disease indications, moving from early-stage research into more advanced clinical trials. By maintaining strong relationships with its core investor base, Arvinas is equipped to navigate the complexities of the biotech landscape, ensuring that its pipeline of novel medicines progresses toward commercialization and long-term value creation for stakeholders.
See full Arvinas company page
